SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
Tweet Send to a Friend
SAGE Therapeutics (NASDAQ: SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails- SAGE-324 (BIIB124) did not demonstrate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
